<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03562273</url>
  </required_header>
  <id_info>
    <org_study_id>HP-00088085</org_study_id>
    <nct_id>NCT03562273</nct_id>
  </id_info>
  <brief_title>GammaPod Registry and Quality of Life Nomogram</brief_title>
  <acronym>GCC 1876</acronym>
  <official_title>Tumor Bed Boost Using a Breast Specific Radiosurgery Device, The GammaPodTM: Registry Study and Evaluation of Quality of Life With Development of Sizing Nomogram</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland, Baltimore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Texas, Southwestern Medical Center at Dallas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Maryland, Baltimore</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a prospective, single arm study (registry) summarizing patient-level&#xD;
      adverse-event and tumor outcomes as well as a number of feasibility and dosimetric&#xD;
      characteristics of delivering a single-fraction boost with the GammaPod.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Breast conserving therapy (BCT), consisting of surgical lumpectomy followed by whole breast&#xD;
      radiation therapy has become the standard of care for treating early-stage breast cancers. In&#xD;
      comparison with mastectomy, BCT demonstrated similar outcomes with superior cosmesis and&#xD;
      reduced psychological and emotional trauma based on multiple randomized trials. At the time&#xD;
      of the lumpectomy, the surgeon removes the tumor and a surrounding rim of normal tissue&#xD;
      (margin), typically leaving surgical clips to help designate the resection cavity or tumor&#xD;
      bed (TB) for the radiation oncologist. The current standard of radiation therapy for breast&#xD;
      cancer is to deliver treatment to the whole breast to 45-50.4Gy in 25 to 28 treatments Monday&#xD;
      through Friday. Following whole breast radiation, a 'boost' is delivered to the TB in order&#xD;
      to deliver 60 - 66Gy to the tumor bed. Two prospective trials have demonstrated a&#xD;
      statistically significant reduction in local failures with the addition of a boost of 10Gy(in&#xD;
      4 fractions @ 2.5 Gy per fraction) or 16 Gy in 8 fractions @ 2 Gy per fraction),&#xD;
      respectively.&#xD;
&#xD;
      Boost treatments can be delivered through a variety of techniques including a single electron&#xD;
      field (used for superficial tumor beds) or multiple photon fields (2 or 3 fields typically)&#xD;
      for tumors that are deep to the skin (usually &gt; 3 cm). With the use of CT simulation to guide&#xD;
      the delivery of the boost, the need for deep TB coverage has become more apparent and now&#xD;
      most patients receive photons for the boost portion of their therapy because the use of&#xD;
      electrons often misses part of the tumor bed. However, when photon beams are used, in&#xD;
      comparison to electrons, more generous margins posterior to the surgical cavity are required&#xD;
      to account for daily set up error and respiratory motion which is not necessary for a single&#xD;
      en face electron field. Furthermore, there are only limited directions along which the&#xD;
      radiation can be directed to the TB, and as a result, large volumes of normal breast tissue&#xD;
      receive a substantial fraction of the prescription dose which can lead to internal scarring&#xD;
      (fibrosis) and poor cosmesis. The largest clinical series evaluating this issue demonstrated&#xD;
      increased fibrosis and worse cosmetic outcome using photons. The clinical target volume for&#xD;
      the boost is the TB, while an additional 1-1.5 cm margin of normal breast tissue is added&#xD;
      isocentrically to account for daily set-up error and respiratory motion to define a planning&#xD;
      target volume. Typically the boost is delivered after the whole breast portion of treatment,&#xD;
      however, in various cases this sequence can be changed. For example, if significant skin&#xD;
      breakdown occurs during the whole breast radiation phase, investigators can stop the whole&#xD;
      breast radiation therapy and change to deliver dose only to the TB while allowing time for&#xD;
      the rest of the breast to heal. This allows a continuous course of therapy to the highest&#xD;
      risk of subclinical disease (i.e. the tumor bed).&#xD;
&#xD;
      Hypofractionation, or delivery of greater than standard 1.8 - 2 Gy fraction sizes per day, is&#xD;
      a method of shortening overall treatment time in early stage breast cancer. Historically,&#xD;
      standard fraction sizes of 1.8-2.0 Gy for whole breast irradiation (WBI) were based primarily&#xD;
      on studies examining squamous cell cancers from cervix and head and neck regions. The smaller&#xD;
      fraction sizes exploited a biological differential in squamous cell cancer fractionation&#xD;
      sensitivity versus normal tissue fractionation sensitivity. This allowed relative sparing of&#xD;
      surrounding normal tissue from low dose per fraction. However, investigators from the United&#xD;
      Kingdom hypothesized that the fractionation sensitivity for adenocarcinoma of the breast is&#xD;
      close to that of the normal breast tissue. Therefore, with increasing fraction size a&#xD;
      sufficiently large reduction of total dose could be implemented to keep late toxicity&#xD;
      constant without reducing the probability of tumor control.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 3, 2019</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>Quality Of Life Evaluations</measure>
    <time_frame>1 year</time_frame>
    <description>Evaluate the quality of life impact shortening treatment by 3-4 fractions may have on a patient via questionnaire(s).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>GammaPod Nomogram construction</measure>
    <time_frame>1 year</time_frame>
    <description>Development of a sizing nomogram for the breast immobilization device using a diagram representing the relations between three or more variable quantities by means of a number of scales, so arranged that the value of one variable can be found by a simple geometric construction, for example, by drawing a straight line intersecting the other scales at the appropriate values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>~10 weeks</time_frame>
    <description>Evaluate acute toxicity of the GammaPod treatment during and up to 1 month following completion of the whole breast +/- LN portion of treatment using a questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment related adverse events as assessed by CTCAE v4.0 post one year from treatment</measure>
    <time_frame>~1.5 years</time_frame>
    <description>The evaluation of long-term toxicity at one year to assess the presence of subcutaneous fibrosis, and fat necrosis.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Breast Cancer Female</condition>
  <arm_group>
    <arm_group_label>GammaPod Quality of Life Evaluations</arm_group_label>
    <description>This study is a prospective, single arm study (registry) summarizing patient-level adverse-event and tumor outcomes as well as a number of feasibility and dosimetric characteristics of delivering a single-fraction boost with the GammaPod.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Quality Of Life Sizing Nomogram</intervention_name>
    <description>If the participant meets the eligibility criteria of the study, and participant chooses to take part, they will receive the tumor bed boost in 8 Gy in 1 fraction just prior to starting whole breast radiation after joining the study. Treatment to the whole breast will begin within 7-8 days from the TB boost (GammaPodTM) treatment.&#xD;
The radiation therapy will take approximately 6 weeks to complete. Follow-up visits specifically for this study will continue for one year, although the physician will continue to follow as part of routine care.</description>
    <arm_group_label>GammaPod Quality of Life Evaluations</arm_group_label>
    <other_name>GammaPod Quality Of Life Sizing Nomogram</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Women with breast cancer&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The patient must sign consent for study participation.&#xD;
&#xD;
          -  The patient must be female and have a diagnosis of an invasive or non-invasive breast&#xD;
             cancer that was treated surgically by a partial mastectomy.&#xD;
&#xD;
          -  The patient must be deemed an appropriate candidate for breast conserving therapy&#xD;
             (i.e. not pregnant, never had radiation to the treated breast, breast size would allow&#xD;
             adequate cosmesis after volume loss from partial mastectomy).&#xD;
&#xD;
          -  Patients with involved lymph nodes are candidates for the study.&#xD;
&#xD;
          -  Surgical margins are negative for invasive (no tumor on ink) or non-invasive breast&#xD;
             cancer (2 mm negative margin).&#xD;
&#xD;
          -  The greatest dimension of the tumor is less than 4cm before surgery.&#xD;
&#xD;
          -  Multifocal disease is allowed if it was removed by a single lumpectomy resection and&#xD;
             the patient remained a candidate for breast conservation.&#xD;
&#xD;
          -  Age 18 years and older.&#xD;
&#xD;
          -  Women of childbearing potential (pre-menopausal defined as having a menstrual period&#xD;
             within the past 1 year) must have a negative serum pregnancy test or complete a&#xD;
             pregnancy waiver form per institutional policy.&#xD;
&#xD;
          -  The surgical cavity is clearly visible on CT images. Of note, clips are not required&#xD;
             but recommended.&#xD;
&#xD;
          -  The patient must weigh less than 150Kg (330lb), which is the limit of the imaging&#xD;
             couch.&#xD;
&#xD;
          -  The patient must be less than 6'6&quot; in height.&#xD;
&#xD;
          -  The patient must feel comfortable in the prone position.&#xD;
&#xD;
          -  Diagnosis of prior contralateral breast cancer is allowed.&#xD;
&#xD;
          -  Diagnosis of synchronous bilateral cancers is allowed. In this case if bilateral&#xD;
             boosts are required, a patient would not have both treatments on the same day.&#xD;
&#xD;
          -  Oncoplastic reduction surgery is allowed if the lumpectomy cavity can be clearly&#xD;
             visualized.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with proven multi-centric carcinoma (tumors in different quadrants of the&#xD;
             breast or tumor separated by at least 4 cm).&#xD;
&#xD;
          -  Prior radiation therapy to that breast or that hemi thorax.&#xD;
&#xD;
          -  Unable to fit into the immobilization breast cup with an adequate seal.&#xD;
&#xD;
          -  Male gender.&#xD;
&#xD;
          -  Patient cannot comfortably be set up in the prone position (i.e. physical disability)&#xD;
&#xD;
          -  Unable to fit into the breast immobilization device due to breast size or other&#xD;
             anatomical reason.&#xD;
&#xD;
          -  Mastectomy is the surgery performed.&#xD;
&#xD;
          -  Patient has received prior radiotherapy to the involved breast.&#xD;
&#xD;
          -  Tumor bed is less than 3 mm from the skin surface.&#xD;
&#xD;
          -  Greater than 50% of the target volume is above the upper border of the table.&#xD;
&#xD;
          -  Patients with skin involvement, regardless of tumor size.&#xD;
&#xD;
          -  Patients with connective tissue disorders specifically systemic lupus erythematosis,&#xD;
             scleroderma, or dermatomyositis.&#xD;
&#xD;
          -  Patients with psychiatric or addictive disorders that would preclude obtaining&#xD;
             informed consent.&#xD;
&#xD;
          -  Patients who are pregnant or lactating due to potential exposure of the fetus to RT&#xD;
             and unknown effects of RT to lactating females.&#xD;
&#xD;
          -  Patients with breast implants/tissue expanders or flap reconstruction.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth M. Nichols, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland, College Park</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elizabeth M. Nichols, M.D.</last_name>
    <phone>410-328-2324</phone>
    <email>enichols1@umm.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Madiha Qutab, M.S.</last_name>
    <phone>410-328-6472</phone>
    <email>madiha.qutab@umm.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Upper Chesapeake Health</name>
      <address>
        <city>Bel Air</city>
        <state>Maryland</state>
        <zip>21014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Romar, BS</last_name>
      <phone>443-643-1877</phone>
      <email>lromar@umm.edu</email>
    </contact>
    <investigator>
      <last_name>Jack Hong, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Central Maryland Oncology Center</name>
      <address>
        <city>Columbia</city>
        <state>Maryland</state>
        <zip>21044</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Madiha Qutab, M.S.</last_name>
      <phone>443-328-6472</phone>
      <email>madiha.qutab@umm.edu</email>
    </contact>
    <investigator>
      <last_name>Sally Cheston, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baltimore Washington Medical Center</name>
      <address>
        <city>Glen Burnie</city>
        <state>Maryland</state>
        <zip>21061</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pilar Strycula, RN, BSN</last_name>
      <phone>410-553-8110</phone>
      <email>Pstrycula@.umm.edu</email>
    </contact>
    <investigator>
      <last_name>Wendla Citron, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UTSouthwestern</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Gamal</last_name>
      <phone>214-645-8519</phone>
      <email>Sara.Gamal@UTSouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Asal Rahimi, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 25, 2018</study_first_submitted>
  <study_first_submitted_qc>June 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 19, 2018</study_first_posted>
  <last_update_submitted>September 9, 2021</last_update_submitted>
  <last_update_submitted_qc>September 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Maryland, Baltimore</investigator_affiliation>
    <investigator_full_name>Department of Radiation Oncology</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Breast Nomogram</keyword>
  <keyword>Breast Cancer Quality of Life</keyword>
  <keyword>GammaPod Registry</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

